VivoSeq
Infectious Disease

Plasmodium Falciparum

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Plasmodium Falciparum is an early-stage landscape with 0 programs across 5 companies. The most active players are Medicines for Malaria Venture, Pfizer, Idorsia Pharmaceuticals Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Medicines for Malaria Venture logo

Medicines for Malaria Venture

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalIdorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.

0 programs

PreclinicalA

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

0 programs

PreclinicalJ

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

31

clinical trials

Completed25 · 81%
Withdrawn2 · 6%
Terminated2 · 6%
Recruiting1 · 3%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

31 trials

A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
Recruiting·ZZydus Lifesciences Limited·Phase 1·NCT05911828·36 enrolled
Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum
Active, not recruiting·JJiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd·Phase 2·NCT06040346·60 enrolled
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00487916·150 enrolled
Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases
Completed·IIndonesia University·Phase 4·NCT01392014·374 enrolled
Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
Completed·RRadboud University Medical Center·N/A·NCT01218893·30 enrolled
Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge
Completed·SSanaria Inc.·Phase 1·NCT02237586·25 enrolled
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Completed·RRadboud University Medical Center·N/A·NCT01422954·20 enrolled
Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02942277·301 enrolled
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua
Completed·SSyamsudin Abdillah,Ph.D, Pharm D·Phase 2·NCT06036030·50 enrolled
Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
Completed·Medicines for Malaria Venture logoMedicines for Malaria Venture·Phase 1·NCT02453581·24 enrolled
Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54
Completed·UU.S. Army Medical Research and Development Command·Phase 1·NCT03882528·12 enrolled
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02627456·409 enrolled
OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation
Completed·Medicines for Malaria Venture logoMedicines for Malaria Venture·Phase 2·NCT01713621·25 enrolled
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02661373·44 enrolled
Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
Completed·RRadboud University Medical Center·N/A·NCT02080026·15 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)